DT-109 Significantly Prevents Progression of Diet-Induced Non-Alcoholic Fatty Liver Disease Kumar Jeetendra | December 4, 2020 Ann Arbor, MI – December 4, 2020 – Life Science Newswire – Rom et al report today that the oral administration of the simple tri-peptide, DT-109 (Patent US8664177B2), prevents both development of non-alcoholic fatty liver disease (NAFLD) and late stage fibrosis in a murine model of diet-induced non-alcoholic steatohepatitis (NASH). The study titled, “Glycine-based treatment …
Rhizen Pharma gets USFDA endorsement for stage one clinical preliminaries for Covid-19 drug Kumar Jeetendra | December 3, 2020 New Delhi, Dec 2 (PTI) Rhizen Pharmaceuticals, a member firm of Alembic Pharmaceuticals, on Wednesday said it has received approval from the US health regulator to commence phase one clinical trials on retroviral oral drug for the treatment of COVID-19. The Switzerland-based firm, which will be a clinical-stage oncology-focussed biopharmaceutical company, has obtained approval for …
Alembic Pharma gets USFDA endorsement for Metolazone tablets Kumar Jeetendra | December 3, 2020 New Delhi, Dec 3 (PTI) Drug firm Alembic Pharmaceuticals on Thursday said it has received approval from the US health regulator for Metolazone tablets, indicated for the treatment of salt and water retention caused by heart failure or kidney disease. The approved product is therapeutically equivalent to the reference listed drug product Zaroxolyn Tablets 2.5 …
Dr Reddy’s, RDIF start clinical preliminaries for Russia’s Sputnik V COVID-19 vaccine in India Kumar Jeetendra | December 2, 2020 Dr Reddy’s Laboratories Ltd and the Russian Direct Investment Fund (RDIF) announced on December 1 the commencement of elastic phase 2/3 clinical trials for COVID-19 vaccine Sputnik V in India after receiving mandatory clearance from the Central Drugs Laboratory, Kasauli in Himachal Pradesh. The Indian drug maker said this will be a multi-centre and randomised …
Keeping Your Chemical Facility Updated: Ways To Improve Maintenance Kumar Jeetendra | December 2, 2020 The chemical industry has been one of the leading sectors in industrial automation for years, where more and more complex systems are being brought together that are allowing to highly improve competitiveness. All this in an environment where safety and environmental regulations are among the most demanding. Therein lies the value of turning maintenance into …
A new nanoemulsion eye drop formulation of a small molecule RUNX1 inhibitor Kumar Jeetendra | November 30, 2020 Boston, MA – 30 November 2020 – Life Science Newswire – A team led by Mass Eye and Ear researchers has developed an eye drop to effectively deliver drugs to the retina and other tissues located in the back of the eye, a new technology with potential application for the treatment of multiple blinding diseases. …
Generis Partner with Cognizant to Deliver Innovative Information Management and Structured Content Authoring Solutions to the Life Sciences Kumar Jeetendra | November 30, 2020 London, UK – 30 November 2020 – Life Science Newswire – Generis, a leader in content and information management systems for regulated industries, announces its strategic partnership with Cognizant, a global provider of information technology, consulting, and business process services, to deliver innovative information management solutions for Life Sciences. This partnership will see Cognizant leverage Generis’ …
Dr. Reddy’s to acquire select Anti-Allergy brands from Glenmark in Russia, Ukraine, Kazakhstan and Uzbekistan Kumar Jeetendra | November 29, 2020 Hyderabad, India. November 28, 2020 — Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has entered into a definitive agreement with Glenmark Pharmaceuticals Ltd. to acquire, subject to completion of certain precedent actions and closing activities, brands Momat Rino …
AMZELL to initiate FDA-approved Phase 3 trial of innovative injectable treatment for infantile epileptic disease Kumar Jeetendra | November 26, 2020 Specialist development pharmaceutical company AMZELL B.V has concluded discussions with the FDA ahead of initiating a Phase 3 trial of its new treatment for infantile epileptic disease, AMZ002. The Phase 3 trial will compare AMZ002 to another active treatment in a superiority study, as a placebo-controlled trial would not be ethical for this patient population. …
Covaxin’s stage 3 preliminaries to begin in Sir JJ Hospital in Mumbai Kumar Jeetendra | November 26, 2020 The phase-3 clinical trials of India’s own COVID-19 vaccine candidate — Covaxin – will begin at Sir JJ Hospital in Mumbai. The medical facility is reportedly the second one in Maharashtra’s capital to start human trials of this vaccine candidate against the novel coronavirus following BMC-run Sion hospital. Covaxin has been developed by the Hyderabad-based …
Dexamethasone use could reduce immune checkpoint inhibitor viability in glioblastoma patients Kumar Jeetendra | November 25, 2020 Bottom Line: One of patients with glioblastoma getting an immune checkpoint inhibitor, people who obtained the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival. Journal Where the Study was Released: Clinical Cancer Research, a journal of the American Association for Cancer Research Author: David A. Reardon, MD, clinical director of the …
BioNTech, Fosun start Phase II preliminary of COVID-19 vaccine in China Kumar Jeetendra | November 25, 2020 BioNTech and Shanghai Fosun Pharmaceutical said on Wednesday they would launch a Phase II clinical trial of BioNTech’s experimental COVID-19 vaccine in China. The vaccine, known as BNT162b2, will be tested on volunteers at the Jiangsu Provincial Center for Disease Control and Prevention to assess safety and immunogenicity, eyeing future acceptance in China, both firms …
